TheraRadar
← Back
Data updated: Jun 28, 2026

MILLICENT PR

Pharma
Pharmaceuticals

MILLICENT PR is a pharmaceutical company with 1 FDA-approved products.

2024
Since
1
Drugs
-
Trials
1
New Drugs (2yr)
Modality:
1 Small Molecules

MILLICENT PR's Key Drugs

MILLICENT PR's core commercial portfolio centers on FEMLYV — its most strategically important drugs approved in the last 15 years.

FEMLYV
Women's Health

Pregnancy prevention

Approved 2024

MILLICENT PR's Recent FDA Approvals

MILLICENT PR secured 1 new FDA approval for novel drugs (NDA/BLA) in the last two years.

FEMLYV NDA
2024-07-22
ethinyl estradiol
Pregnancy prevention

MILLICENT PR's Therapeutic Areas

Disease areas where MILLICENT PR has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.

No indication data

MILLICENT PR Pipeline Snapshot

Active clinical trials for MILLICENT PR across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • FEMLYV leads revenue
  • • Drug-level revenue analysis

Trial Catalysts

  • • Active trial monitoring
  • • Phase 3 readout tracking

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling